why choose us

First received: September 15, 2023

Clinical Trial: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Chronic Myelomonocytic Leukemia

Study Type: INTERVENTIONAL


Official Title: CD4CAR T Cell Therapy for CMML

Brief Summary: This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory CMML.Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells.

Read more